FDA issues draft industry guidance for early-stage Alzheimer's disease

|By:, SA News Editor

Alzheimer's disease (AD) has stubbornly resisted a range of potential treatments over the years. In an effort to help drug developers, the FDA has released draft guidance on early-AD diagnostic criteria and possible endpoints for mid-stage and late-stage studies.

Selected AD-related tickers: (MRK +0.9%)(CDXC +1.1%)(AVXL +0.2%)(OTCQX:IGXT -0.6%)(VTVT)(OTCPK:TKPYY +0.2%)(BIIB +1%)(AXSM)(DNLI +9.4%)(AMGN +1.9%)(NVS +0.9%)(PTIE -0.9%)(ABBV +0.9%)(OTCPK:ESALY +4.4%)(IONS +1.9%)(AXON +3.4%)(BHVN -1.2%)(ACIU +4.6%)

Subscribe for full text news in your inbox